A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).

U. Emmenegger; S. R. Berry; C. M. Booth; S. S. Sridhar; E. Winquist; N. Bandali; A. Chow; R. Kerbel; Y. Ko

doi:10.1200/jco.2011.29.15_suppl.e15152

A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e15152 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e15152-e15152 ◽

Cited By ~ 1

Author(s):

U. Emmenegger ◽

S. R. Berry ◽

C. M. Booth ◽

S. S. Sridhar ◽

E. Winquist ◽

...

Keyword(s):

Prostate Cancer ◽

Maintenance Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Castration Resistant

Download Full-text

A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps246 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS246-TPS246 ◽

Cited By ~ 2

Author(s):

U. Emmenegger ◽

S. S. Sridhar ◽

C. M. Booth ◽

R. Kerbel ◽

S. R. Berry ◽

...

Keyword(s):

Prostate Cancer ◽

Maintenance Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Castration Resistant

Download Full-text

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdx487 ◽

2017 ◽

Vol 28 (11) ◽

pp. 2741-2746 ◽

Cited By ~ 7

Author(s):

K. Fizazi ◽

A. Ulys ◽

L. Sengeløv ◽

M. Moe ◽

S. Ladoire ◽

...

Keyword(s):

Prostate Cancer ◽

Maintenance Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Docetaxel Chemotherapy

Download Full-text

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-010-1389-7 ◽

2010 ◽

Vol 67 (4) ◽

pp. 927-933 ◽

Cited By ~ 15

Author(s):

Srikala S. Sridhar ◽

Christina M. Canil ◽

Kim N. Chi ◽

Sebastien J. Hotte ◽

Scott Ernst ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Antisense Oligonucleotide ◽

Phase Ii Study ◽

Line Treatment ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Castration Resistant ◽

First Line Treatment

Download Full-text

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer

Cancer Medicine ◽

10.1002/cam4.3806 ◽

2021 ◽

Author(s):

Judith Passildas‐Jahanmohan ◽

Jean‐Christophe Eymard ◽

Mélanie Pouget ◽

Fabrice Kwiatkowski ◽

Isabelle Van Praagh ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Castration Resistant ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

7036 Phase II study with pharmacodynamic evaluation of docetaxelprednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71414-4 ◽

2009 ◽

Vol 7 (2) ◽

pp. 417

Author(s):

A. Fontana ◽

L. Galli ◽

L. Derosa ◽

G. Minuti ◽

M. D'Arcangelo ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Castration Resistant ◽

Metronomic Cyclophosphamide ◽

First Line Treatment

Download Full-text

Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

British Journal of Cancer ◽

10.1038/bjc.2012.339 ◽

2012 ◽

Vol 107 (5) ◽

pp. 808-813 ◽

Cited By ~ 14

Author(s):

T M Beer ◽

D C Smith ◽

A Hussain ◽

M Alonso ◽

J Wang ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Phase Ii ◽

Department Of Defense ◽

Phase Ii Study ◽

Cancer Clinical Trials ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Castration Resistant

Download Full-text

Randomized phase II study of abiraterone acetate (AA) maintenance in combination with docetaxel after disease progression to AA in metastatic castration resistant prostate cancer (mCRPC): Preliminary safety results of first line AA treatment—ABIDO-SOGUG Trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e16022 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e16022-e16022 ◽

Cited By ~ 1

Author(s):

Ignacio Duran ◽

Enrique Grande ◽

Daniel E. Castellano ◽

Albert Font ◽

M Isabel Sáez ◽

...

Keyword(s):

Prostate Cancer ◽

Disease Progression ◽

Phase Ii ◽

Phase Ii Study ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Castration Resistant ◽

Randomized Phase Ii

Download Full-text

Faculty Opinions recommendation of A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3350956.3039058 ◽

2010 ◽

Author(s):

Yoshihiko Hirao ◽

Kiyohide Fujimoto

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Transdermal Estradiol ◽

Docetaxel Chemotherapy

Download Full-text

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-12-2605 ◽

2012 ◽

Vol 19 (1) ◽

pp. 215-224 ◽

Cited By ~ 58

Author(s):

Charles J. Ryan ◽

Mark Rosenthal ◽

Siobhan Ng ◽

Joshi Alumkal ◽

Joel Picus ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Biomarker Analysis

Download Full-text

MP87-11 INTERIM ANALYSIS OF AN OPEN LABEL PHASE II STUDY OF ENZALUTAMIDE AND RADIUM RA 233 DICHLORIDE IN SYMPTOMATIC, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS.

The Journal of Urology ◽

10.1016/j.juro.2018.02.2911 ◽

2018 ◽

Vol 199 (4S) ◽

Author(s):

Neal Shore ◽

Paul Schellhammer ◽

Ronald Tutrone ◽

Neil Mariados ◽

Stacey Harrelson

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Study ◽

Castration Resistant Prostate Cancer ◽

Open Label ◽

Castration Resistant ◽

Open Label Phase

Download Full-text